Epithelial-to-Mesenchymal Transition as a Potential Target for Antineoplastic TherapiesSushma R Rao1 and Aparna Jayachandran2-6*
- *Corresponding Author:
- Aparna Jayachandran
Liver Cancer Unit, Gallipoli Medical Research Institute
School of Medicine, The University of Queensland
Lower Lobby Level, Administration Building
Greenslopes Private Hospital
Newdegate Street, Greenslopes QLD 4120, Australia
Tel: +61(7) 33460695
E-mail: [email protected]
Received Date: November 3, 2015 Accepted Date: November 5, 2015 Published Date: November 9, 2015
Citation: Rao SR, Jayachandran A (2015) Epithelial-to-Mesenchymal Transition as a Potential Target for Antineoplastic Therapies. J Cancer Clin Trials 1:e103. doi: 10.4172/jcct.1000e103
Copyright: © 2015 Rao SR and Jayachandran A. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Epithelial-to-mesenchymal transition (EMT) is a multi-step reprograming process resulting in a phenotype switch from an epithelial to a mesenchymal state. This phenotype switching of cells, long been studied for its role in development, is now emerging as a crucial process that endows tumor cells with migratory and invasive properties, enriches stem cell-like attributes, enhances drug resistance, prevents apoptosis and contribute to immunosuppression. A comprehensive understanding of EMT cellular program will enable identification and development of potential EMT-targeted antitumor therapeutic strategies. This Editorial briefly describes recent evidence of EMT as a driver of malignancy and evaluates various strategies to target EMT in cancer.